S

Sanofi

Global pharma company; vaccines and R&D

RWE Project Lead

Full-TimeUpdated on 10/23/2026Deadline 10/31/26
$148.5k - $214.5k
Junior
Master's, PhD
Cambridge, MA, USA
In Person
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • A PhD or MSc in Health Sciences with a quantitative background, Epidemiology, or Public Health.
  • At least 2 years of previous experience in a real-world or clinical project in industry.
  • Proven capability to deliver complex projects.
  • Understanding of therapeutic areas relevant to Sanofi, such as immunology and inflammation, Neuroscience, or rare diseases, as well as current needs and latest innovations in clinical development and evidence generation.
  • Understanding of real-world evidence, data analytics, and statistics.
  • Understanding of the legal and regulatory environment influencing clinical development plans, labelling, and promotional claims.
  • Past experience with or enthusiasm for big data and modern technology stack environments.
Responsibilities
  • Lead high-impact projects at project level within specific therapeutic areas and across functions, leveraging real-world evidence artificial intelligence evidence-generation platforms and other real-world evidence assets in response to clinical development needs and current or future pipeline.
  • Drive real-world evidence projects prioritized by Clinical Development RWE Portfolio Heads based on clinical development evidence needs and current or future molecule pipelines, using a core real-world evidence evidence-generation platform.
  • Work closely with internal partners, including Global Project Team members, the Clinical Science Organization, Research, the Digital Office, and Global Regulatory teams, to fulfill therapeutic-area and asset needs and ambitions.
  • Execute the project-specific roadmap to ensure successful project delivery.
  • Bring project deliverables to Global Project Teams, highlight and execute portfolio strategies, and source data required to run projects.
  • Lead multidisciplinary teams and ensure effective project execution plans and timelines.
  • Coordinate with RWE Portfolio Heads, Global Project Teams, and other key stakeholders to design project minimum viable products, identify and address user needs, align stakeholders, and translate needs into actionable project goals and deliverables.
  • Create project business cases, document and report project activities, and define system requirements and dependencies with other projects.
  • Inform the roadmap for real-world evidence platform projects by overseeing end-to-end project development and dependencies.
  • Ensure access modalities to fit-for-purpose datasets in collaboration with relevant Sanofi stakeholders in relevant therapeutic areas.
  • Interact externally to drive adoption of real-world evidence in clinical development at FDA and EMA level.
  • Generate and discuss regulatory and other real-world evidence packages.
  • Ensure proper dissemination and use of study outputs to support Clinical Development objectives.
Desired Qualifications
  • Well-developed conceptual thinking skills and the capability to access internal and external resources.
  • Successful experience working in a global and matrixed environment.
  • Ability to collaborate externally and internally with key customers and stakeholders.
  • Strong project management skills and experience.
  • Proven leadership and stakeholder management skills.
  • Innovative mindset.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...